BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+11.22%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$10.3B
AUM Growth
+$10.3B
(+14%)
Cap. Flow
+$826M
Cap. Flow
% of AUM
8.01%
Top 10 Holdings %
Top 10 Hldgs %
81.62%
Holding
101
New
12
Increased
23
Reduced
8
Closed
11
Top Buys
| 1 |
Insmed
INSM
|
$235M |
| 2 |
Summit Therapeutics
SMMT
|
$198M |
| 3 |
Alkermes
ALKS
|
$55.1M |
| 4 |
Revolution Medicines
RVMD
|
$52.5M |
| 5 |
Structure Therapeutics
GPCR
|
$44.5M |
Top Sells
| 1 |
CRISPR Therapeutics
CRSP
|
$22.3M |
| 2 |
argenx
ARGX
|
$22M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$17.6M |
| 4 |
TSVT
2seventy bio
TSVT
|
$12.3M |
| 5 |
Akero Therapeutics
AKRO
|
$12M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ONC
1
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $2.13B | 20.66% | 8,799,053 | – | – |
|
2
Incyte
INCY
$16.5B
| $2.09B | 20.31% | 30,743,275 +3,322 | +0% | +$226K |
|
3
Acadia Pharmaceuticals
ACAD
$4.38B
| $925M | 8.98% | 42,896,690 +18,774 | +0% | +$405K |
|
|
4
Insmed
INSM
$28.8B
| $776M | 7.53% | 7,712,900 +2,332,274 | +43% | +$235M |
|
|
5
Summit Therapeutics
SMMT
$17.6B
| $718M | 6.96% | 33,722,974 +9,298,109 | +38% | +$198M |
|
6
Madrigal Pharmaceuticals
MDGL
$9.76B
| $598M | 5.8% | 1,976,018 +1,428 | +0.1% | +$432K |
|
7
Rhythm Pharmaceuticals
RYTM
$6.85B
| $354M | 3.44% | 5,604,483 | – | – |
|
|
8
Revolution Medicines
RVMD
$7.1B
| $345M | 3.34% | 9,364,972 +1,428,000 | +18% | +$52.5M |
|
9
Kymera Therapeutics
KYMR
$2.95B
| $290M | 2.82% | 6,651,429 +655,500 | +11% | +$28.6M |
|
|
10
Alkermes
ALKS
$4.78B
| $183M | 1.78% | 6,410,603 +1,927,318 | +43% | +$55.1M |
|
11
Replimune Group
REPL
$422M
| $103M | 1% | 11,045,336 | – | – |
|
12
Ultragenyx Pharmaceutical
RARE
$2.89B
| $101M | 0.98% | 2,772,692 +1,196,578 | +76% | +$43.5M |
|
13
Edgewise Therapeutics
EWTX
$1.51B
| $95.8M | 0.93% | 7,305,940 +1,150,000 | +19% | +$15.1M |
|
14
AbCellera Biologics
ABCL
$1.25B
| $94.4M | 0.92% | 27,525,640 | – | – |
|
15
Immunovant
IMVT
$2.56B
| $87.3M | 0.85% | 5,457,881 | – | – |
|
|
GRAL
16
GRAIL, Inc. Common Stock
GRAL
$1.18B
| $83.8M | 0.81% | 1,630,125 | – | – |
|
17
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $78.2M | 0.76% | 2,824,669 +6,346 | +0.2% | +$176K |
|
|
BCYC
18
Bicycle Therapeutics
BCYC
$511M
| $75.7M | 0.73% | 10,885,357 | – | – |
|
19
Immunocore
IMCR
$1.62B
| $72.9M | 0.71% | 2,322,656 | – | – |
|
20
Celcuity
CELC
$2.17B
| $72.8M | 0.71% | 5,450,445 +1,192,710 | +28% | +$15.9M |
|
21
Kodiak Sciences
KOD
$478M
| $64.6M | 0.63% | 17,310,490 | – | – |
|
22
Immatics
IMTX
$619M
| $54.7M | 0.53% | 10,168,901 +2,893,071 | +40% | +$15.6M |
|
23
Stoke Therapeutics
STOK
$1.08B
| $52.6M | 0.51% | 4,633,838 | – | – |
|
24
Denali Therapeutics
DNLI
$2.23B
| $52.2M | 0.51% | 3,731,695 | – | – |
|
|
25
Structure Therapeutics
GPCR
$1.11B
| $52M | 0.5% | 2,508,767 +2,147,202 | +594% | +$44.5M |
|